LPCN (Lipocine Inc) Earnings per share for the last four quarters

Lipocine Corp (LPCN) - corporate logo

Lipocine Inc. effectively delegates mass drug production to global CMO networks while maintaining strict oversight of contracts. Innovations in oral hormone delivery allow the company to command premium pricing during licensing. The business model relies on third-party molecule synthesis without owning its own plants. In the EPS YoY TTM shift metric, the value -33.00 serves as the current indicator capturing the market consensus on the annual profit growth rate.

LPCN lipocine.com Net earnings per share (EPS TTM) (02/11/2024 - 11/17/2026)

LPCN (Lipocine Inc.): analytical breakdowns and indicator data

- price and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:LPCN (Lipocine Inc)
Core merchandise of Lipocine Corporation

This indicator measures the annual rate of change in net income per share over the last twelve months, allowing for a real-time assessment of capital generation efficiency. By analyzing the EPS YoY TTM percentage trend, an investor can identify the critical dependence of Lipocine Inc. (LPCN) on FDA approvals and the risks of shareholder dilution resulting from regular secondary offerings.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|SLNO - Earnings per share for the last twelve months|FOLD: Earnings per share for the last twelve months|ETNB: Net earnings per share (EPS TTM)|AGIO - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months rezolutebio.com (RZLT)|Net earnings per share for the last 12 months lexpharma.com LXRX|Net earnings per share (EPS TTM) MBX (MBX Biosciences)|Altimmune Corp - Earnings per share for the last twelve months|Aardvark Therapeutics Inc. - Net earnings per share (EPS TTM)|SGMT - Net earnings per share (EPS TTM)|BioAge Labs (BIOA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months biomeafusion.com (BMEA)|Earnings per share for the last twelve months Quince Therapeutics, Inc.|Net earnings per share for the last 12 months Fractyl (GUTS)|Net earnings per share for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Net earnings per one share for the last twelve months|Pluri Inc. - Net earnings per share for the last 12 months|Net earnings per share for the trailing year Synlogic Corp|MTNB - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS